Menu
Annual · values20252024202320222021
Operating Cash Flow-7.16 M USD-5.27 M USD-3.65 M USD-5.31 M USD-2.40 M USD
Depreciation & Amortization227406 USD193139 USD162670 USD193621 USD186388 USD
Stock-Based Compensation105368 USD287455 USD456001 USD1.19 M USD177489 USD
Capital Expenditures21528 USD5115 USD0 USD
Cash Flow from Investing-203902 USD-321937 USD-119522 USD-207870 USD-102005 USD
Cash Flow from Financing18.95 M USD5.03 M USD3.31 M USD6.55 M USD2.94 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-7.19 M USD-5.28 M USD-3.65 M USD

Aclarion Inc. is a healthcare technology company that develops innovative diagnostic solutions for spine-related conditions, particularly low back and neck pain. The company combines magnetic resonance spectroscopy (MRS) imaging with proprietary augmented-intelligence algorithms to create software-as-a-service (SaaS) solutions that help physicians personalize treatment plans and optimize clinical outcomes. The company's primary offering is the NOCISCAN Suite, which uses MRS capabilities to noninvasively analyze the chemical composition of intervertebral discs in the spine. Aclarion's suite includes the NOCISCAN MRS Exam Protocol for standard lumbar MRI exams, the NOCISCAN Post-Processor Suite with NOCICALC and NOCIGRAM applications that process spectroscopy data and calculate degenerative pain biomarkers, and complementary imaging data transfer platforms. By leveraging artificial intelligence to assist in quality control processes and proprietary biomarkers, Aclarion aims to address unmet clinical needs in musculoskeletal pain management and help patients achieve improved health outcomes and pain relief.